IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans

Clinical Immunology

Volumn 130, Issue 3, 2009, Pages 304-312

  Shen, Long ^a,b   Suresh, Lakshmanan ^c   Li, Hong ^a,b,d   Zhang, Chongjie ^a,b,d   Kumar, Vijay ^c   Pankewycz, Oleh ^a,b   Ambrus Jr , Julian L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b GATES VASCULAR INSTITUTE AT KALEIDA HEALTH   (United States)

^c IMMCO Diagnostics Inc   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Animal model; IL 14; ; Sj gren's disease;

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 14; INTERLEUKIN 14ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LACRIMAL GLAND; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PAROTID GLAND; PATHOPHYSIOLOGY; PLASMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; LUNG; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVARY GLANDS; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 59349087482     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.10.006     Document Type: Article

References (45)

1. Fox R.I. Sjogren's syndrome. Lancet 366 (2005) 321-331
2. Delaleu N., Jonsson R., and Koller M.M. Sjogren's syndrome. Eur. J. Oral Sci. 113 (2005) 101-113
3. Lazarus M.N., and Isenberg D.A. Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann. Rheum. Dis. 64 (2005) 1062-1064
4. Hansen A., Lipsky P.E., and Dorner T. Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr. Opin. Rheumatol. 17 (2005) 558-565
5. Hsu T.C., Chang C.H., Lin M.C., Liu S.T., Yen T.J., and Tsay G.J. Anti-CENP-H antibodies in patients with Sjogren's syndrome. Rheumatol. Int. 26 (2006) 298-303
6. Gordon T.P., Bolstad A.I., Rischmueller M., Jonsson R., and Waterman S.A. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 34 (2001) 123-132
7. Zufferey P., Meyer O.C., Grossin M., and Kahn M.F. Primary Sjogren's syndrome (SS) and malignant lymphoma-a retrospective cohort study of 55 patients with SS. Scand. J. Rheumatol. 24 (1995) 342-345
8. Royer B., CazalsHatem D., Sibilia J., Agbalika F., Cayuela J.M., Soussi T., Maloisel F., Clauvel J.P., Brouet J.C., and Mariette X. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90 (1997) 766-775
9. Voulgarelis M., Dafni U.G., Isenberg K.A., and Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome-a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome. Arthritis Rheum. 42 (1999) 1765-1772
10. Pertovaara M., Pukkala E., Laippala P., Miettinen A., and Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann. Rheum. Dis. 60 (2001) 467-472
11. Theander E., Manthorpe R., and Jacobsson L.T.H. Mortality and causes of death in primary Sjogren's syndrome-a prospective cohort study. Arthritis Rheum. 50 (2004) 1262-1269
12. Anaya J.M., McGuff H.S., Banks P.M., and Talal N. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin. Arthritis Rheum. 25 (1996) 337-346
13. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., Costa J., Decker J.L., and Chused T.M. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. 89 (1978) 888-892
14. Daniels T.E. Evaluation, differential diagnosis, and treatment of xerostomia. J. Rheumatol. 61 Suppl. (2000) 6-10
15. Manoussakis M.N., Georgopoulou C., Zintzaras E., Spyropoulou M., Stavropoulou A., Skopouli F.N., and Moutsopoulos H.M. Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. Arthritis Rheum. 50 (2004) 882-891
16. Shen L., Zhang C., Wang T., Brooks S., Ford R.J., Lin-Lee Y.C., Kasianowicz A., Kumar V., Martin L., Liang P., Cowell J., Ambrus J., and J.L. Development of autoimmunity in interleukin-14alpha transgenic mice. J. Immunol. 177 (2006) 5676-5686
17. Mariette X. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk. Lymphoma 33 (1999) 93-99
18. RamosCasals M., Font J., GarciaCarrasco M., Brito M.P., Rosas J., CalvoAlen J., Pallares L., Cervera R., and Ingelmo M. Primary Sjogren syndrome-hematologic patterns of disease expression. Medicine 81 (2002) 281-292
19. Manganelli P., Fietta P., and Quaini F. Hematologic manifestations of primary Sjogren's syndrome. Clin. Exp. Rheumatol. 24 (2006) 438-448
20. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., Daniels T.E., Fox P.C., Fox R.I., Kassan S.S., Pillemer S.R., Talal N., and Weisman M.H. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61 (2002) 554-558
21. Freeman W.M., Walker S.J., and Vrana K.E. Quantitative RT-PCR: pitfalls and potential. Biotechniques 26 (1999) 112+
22. Shen L., Zhang C., Ambrus J.L., and Wang J.H. Silencing of human c-myc oncogene expression by poly-DNP-RNA. Oligonucleotides 15 (2005) 23-35
23. Ford R.J., Shen L., Lin-Lee Y.C., Pham L.V., Multani A., Zhou H.J., Tamayo A.T., Zhang C., Hawthorn L., Cowell J.K., and Ambrus Jr. J.L. Development of a murine model for blastoid variant mantle cell lymphoma. Blood 109 (2007) 4899-4906
24. Tran S.D., Kodama S., Lodde B.M., Szalayova I., Key S., Khalili S., Faustman D.L., and Mezey E. Reversal of Sjogren's-like syndrome in non-obese diabetic mice. Ann. Rheum. Dis. 66 (2007) 812-814
25. Jonsson M.V., Delaleu N., Brokstad K.A., Berggreen E., and Skarstein K. Impaired salivary gland function in NOD mice-association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 54 (2006) 2300-2305
26. Pijpe J., Kalk W.W., Bootsma H., Spijkervet F.K., Kallenberg C.G., and Vissink A. Progression of salivary gland dysfunction in patients with Sjogren's syndrome. Ann. Rheum. Dis. 66 (2007) 107-112
27. Tapinos N.I., Polihronis M., Tzioufas A.G., and Moutsopoulos H.M. Sjogren's syndrome. autoimmune epithelitis. Adv. Exp. Med. Biol. 455 (1999) 127-134
28. Yarom N., Dayan D., Buchner A., and Vered M. Immunoprofile of focal lymphocytic infiltration in minor salivary glands of healthy individuals. Oral. Dis. 13 (2007) 274-278
29. Kruize A.A., Hene R.J., van der Heide A., Bodeutsch C., de Wilde P.C., van Bijsterveld O.P., de Jong J., Feltkamp T.E., Kater L., and Bijlsma J.W. Long-term followup of patients with Sjogren's syndrome. Arthritis Rheum. 39 (1996) 297-303
30. GarciaCarrasco M., RamosCasals M., Rosas J., Pallares L., CalvoAlen J., Cervera R., Font J., and Ingelmo M. Primary Sjogren syndrome-clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81 (2002) 270-280
31. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., and Jacobsson L.T.H. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 65 (2006) 796-803
32. RamosCasals M., Anaya J.M., GarciaCarrasco M., Rosas J., Bove A., Claver G., Diaz L.A., Herrero C., and Font J. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine 83 (2004) 96-106
33. Parambil J.G., Myers J.L., Lindell R.M., Matteson E.L., and Ryu J.H. Interstitial lung disease in primary Sjogren syndrome. Chest 130 (2006) 1489-1495
34. Quismorio Jr. F.P. Pulmonary involvement in primary Sjogren's syndrome. Curr. Opin. Pulm. Med. 2 (1996) 424-428
35. Kaufman I., Schwartz D., Caspi D., and Paran D. Sjogren's syndrome-not just sicca: renal involvement in Sjogren's syndrome. Scand. J. Rheumatol. 37 (2008) 213-218
36. Jonsson R., Haga H.J., and Gordon T.P. Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand. J. Rheumatol. 29 (2000) 341-348
37. Gannot G., Lancaster H.E., and Fox P.C. Clinical course of primary Sjogren's syndrome: salivary, oral, and serologic aspects. J. Rheumatol. 27 (2000) 1905-1909
38. Tucker A.S. Salivary gland development. Semin. Cell Dev. Biol. 18 (2007) 237-244
39. Ramos-Casals M., Brito-Zeron P., and Font J. Lessons from diseases mimicking Sjogren's syndrome. Clin. Rev. Allergy Immunol. 32 (2007) 275-283
40. Gao J.H., Killedar S., Cornelius J.G., Nguyen C., Cha S.H., and Peck A.B. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J. Autoimmun. 26 (2006) 90-103
41. Ohno K., Hattori T., Kagami H., and Ueda M. Effects of preceding sialadenitis on the development of autoimmunity against salivary gland. Oral Dis. 13 (2007) 158-162
42. Goeb V., Salle V., Duhaut P., Jouen F., Smail A., Ducroix J.P., Tron F., LeLoet X., and Vittecoq O. Clinical significance of autoantibodies recognizing Sjogren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjogren's syndrome. Clin. Exp. Immunol. 148 (2007) 281-287
43. Haneji N., Nakamura T., Takio K., Yanagi K., Higashiyama H., Saito I., Noji S., Sugino H., and Hayashi Y. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276 (1997) 604-607
44. Griffith K.J., Chan E.K.L., Lung C.C., Hamel J.C., Guo X.Y., Miyachi K., and Fritzler M.J. Molecular cloning of a novel 97-kd golgi complex autoantigen associated with Sjogren's syndrome. Arthritis Rheum. 40 (1997) 1693-1702
45. Cha S.H., Singson E., Cornelius J., Yagna J.P., Knot H.J., and Peck A.B. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J. Rheumatol. 33 (2006) 296-306